|
Biogen – Ahead of Q2 Earnings on Thursday
Proactive Investors USA & Canada AVONEX® (interferon beta-1a), TYSABRI® (natalizumab), and RITUXAN® (rituximab) are Biogen’s other primary drugs in the MS indication. These three brought in the vast majority of the company’s $1.4 B in quarterly revenues ($736 million, $275 million, … |
Autism Daily NewscastGluten Antibodies and AutismAutism Daily NewscastA team of American researchers have found a potential link between gluten antibodies and children with autism. The researchers at Columbia University Medical Center (CUMC) found this…
|
NICE ‘minded to say no’ to MabThera
PharmaTimes NICE has been examining MabThera (rituximab)’s use in its licensed indication for inducing remission, in combination with glucocorticoids, in adults with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, an inflammatory autoimmune … |
|
Biogen Idec’s long-acting beta interferon moves ahead in MS
PMLiVE Biogen Idec’s also sells Tysabri (natalizumab) for MS, which is expected to remain an important treatment option for some patients, and is also bringing a new anti-CD-25 antibody called daclizumab through late-stage development in partnership with Idec. |
|
UK’s NICE calls for more data to consider Roche drug for a type of vasculitis
The Pharma Letter UK drug watchdog the National Institute for Health and Care Excellence (NICE) has today (July 23) published draft guidance on Swiss drug major Roche’s (ROG: SOX) blockbuster cancer drug MabThera (rituximab), which is also licensed for inducing … NICE demands more data from Roche for MabThera in rare autoimmune diseasePMLiVE |
PD-1 AntibodiesHealioThis activity will review data on the efficacy, safety, and response patterns observed with PD-1 in patients with advanced melanoma. This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc.,…
|
아스텔라스 면역억제제 ‘아스타그랍’ 승인장기이식 거부반응 효과 …임상 3상 시험 …
의약뉴스 아스타그랍은 1일 1회 복용하는 경구약으로 바실릭시맙(basiliximab)을 포함하거나 혹은 포함하지 않고 마이코페노레이트 모페틸(mycophenolate mofetil)과 코르티코스테로이드(corticosteroids) 약물과 병용해 이식거부반응을 예방한다. 이번 승인은 1093명의 환자 … |
MedPage Today |
U.S. Launch of Astellas’ Astagraf XL – Analyst Blog
NASDAQ … received approval for Astagraf XL (tacrolimus extended-release capsules) in the U.S. for the prevention of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab … Long-Release Tacrolimus Wins FDA NodMedPage Today New Treatment Option for Kidney Transplant RecipientsMonthly Prescribing Reference FDA approves Astellas once-daily organ rejection drugPharmaTimes Genetic Engineering News –NephrologyNews.com –The Pharma Letter all 8 news articles » |
|
GAUGUIN: Higher Obinutuzumab Dose Shows Promise in Non-Hodgkin …
Cancer Network “Given that CD20 has proved to be a highly successful target antigen for immunotherapeutic approaches in hematologic malignancies, the development of novel anti-CD20 antibodies with functional activity different from that of rituximab may translate to … |
|
Promising Radioimmunotherapy Option for Some Lymphomas
Cancer Network A phase I/II study found that radioimmunotherapy with 177Lu and the anti-CD20 antibody rituximab along with the chelator DOTA is safe and feasible for treatment of relapsed follicular, mantle cell, or other indolent lymphomas. “Radioimmunotherapy … |